Key points from article :
ScienceMachine, a London-based AI startup founded in 2025, has raised €2.9 million in pre-seed funding to revolutionise how biotech and pharmaceutical companies analyse research data. The company is developing fully autonomous AI agents designed to drastically accelerate the pace of scientific discovery by automating complex data analysis tasks. The round was led by Revent and Nucleus Capital, with participation from Juniper and strategic angel investors, and will support product development and team expansion, especially in sales and pharma partnerships.
At the heart of ScienceMachine’s innovation is Sam, an always-on AI agent that acts as a bioinformatician, analysing raw experimental data from lab to clinic without human intervention. Sam automates the full analysis pipeline—from data cleaning to visualisation—providing researchers with insights in hours instead of months. This capability helps solve a pressing issue in life sciences: the shortage of skilled data scientists and the time-consuming nature of manual data analysis. The platform integrates directly with lab workflows and databases, offering high-quality results at a fraction of the usual time and cost.
What makes ScienceMachine particularly notable is its lean structure and execution speed. With a founding team of just two people and no marketing spend, the company has already signed multiple contracts and is outpacing competitors by delivering production-level AI automation. Investors have praised their execution, product quality, and understanding of the market, calling the startup one of the most promising players in AI-driven science.
Looking ahead, ScienceMachine aims to expand from serving biotech startups to larger pharmaceutical companies, where the demand for scalable data solutions is even greater. Their mission is clear: to make scientific discovery faster, more accessible, and significantly more efficient by embedding AI agents like Sam into the core of biomedical research.
